BC
REGN icon

Belmont Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Belmont Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-17
Closed -$12.2K – 194
2023
Q2 		$12.2K Sell
17
-5
-23% -$3.85K 0.01% 132
2023
Q1 		$18.1K Hold
22
– – 0.02% 69
2022
Q4 		$16K Hold
22
– – 0.02% 76
2022
Q3 		$15K Buy
+22
New +$13.8K 0.02% 62

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Belmont Capital's REGN Position: Q3 2023 in Review

Belmont Capital sold out of Regeneron Pharmaceuticals (REGN) in Q3 2023, closing a stake of 17 shares — an estimated $12.2K sold.

Belmont Capital first reported a position in REGN in Q3 2022 and held it in 4 quarters. The position peaked at $18.1K in Q1 2023. 1,177 funds tracked by Wall St. Rank hold REGN as of Q3 2023.

  • Belmont Capital reported no remaining Regeneron Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Belmont Capital sold 17 Regeneron Pharmaceuticals shares in Q3 2023, an estimated $12.2K.
  • Belmont Capital first reported a position in Regeneron Pharmaceuticals in Q3 2022 and held it in 4 quarters.
  • Belmont Capital's Regeneron Pharmaceuticals position peaked at $18.1K in Q1 2023.
  • 1,177 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2023.

Based on Belmont Capital's 13F filing for Q3 2023, filed 13 Nov 2023.